Purpose: The aim of this study was to analyse the results of treatment with indomethacin as first line treatment in children and adults with Langerhans cell histiocytosis (LCH). Methods: Between 1999 and 2018, 47 patients with a diagnosis of LCH (CD1a+, S100+, CD207+) with a median age of 29 years (range 1-66) were treated with indomethacin 2 mg/Kg/day (maximum dose 150 mg/day) as first line (21 in combination with surgery and/or chemotherapy). Twentyseven patients (57.5%) had single system diseases (SS-LCH), 20 unifocal (74%) and 7 multifocal, and 20 (42.5%) presented multi-system involvement (MS-LCH). BRAF mutation analysis was available in 8/47 patients. Results: Thirty-eight of the 47 patients (81%) were evaluable for response. Two patients (4%) discontinued indomethacin due to toxicity. Considering patients evaluable for response, the median treatment duration was 3 months. All patients obtained a response, that was complete (CR) in 23 (60%) and intermediate (IR) in 15 (40%). Considering the disease status, 16/24 (66.6%) SS-LCH and 7/14 (50%)MS-LCH patients achieved a CR, while an IR was recorded in 8/24 (33.4%) SSLCH and in 7/14 (50%) MS-LCH patients. The CR rate was higher in patients treated with indomethacin as a single agent regimen (14/2, 66.6%) than in those who received a combination regimen (9/17, 53%). Disease reactivation occurred in 2/38 (5%) patients after 3 and 17 months, respectively, from treatment suspension. Three of 8 tested patients (37.5%) were BRAF mutated; all of them obtained a durable CR without recurrence. The most common toxicity was hypertension, recorded in 5/38 (13%) patients. All patients are alive. Conclusion: Our experience shows that indomethacin, used as single agent or in combination, is an effective first-line treatment, for SS-LCH and MS-LCH with bone involvement.

INDOMETHACIN AS FIRST LINE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS (LCH). A 20-YEAR EXPERIENCE OF A SINGLE CENTRE / Rizzo, Lorenzo; Santopietro, Michelina; Palumbo, Giovanna; Cardarelli, Luisa; Moleti, MARIA LUISA; Malaspina, Francesco; Testi, Anna Maria; Robin, Foà; Giona, Fiorina. - In: PEDIATRIC BLOOD & CANCER. - ISSN 1545-5009. - (2018). ((Intervento presentato al convegno Annual Meeting of the Histiocyte Society tenutosi a LISBONA.

INDOMETHACIN AS FIRST LINE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS (LCH). A 20-YEAR EXPERIENCE OF A SINGLE CENTRE.

Lorenzo Rizzo;Michelina Santopietro;Giovanna Palumbo;Maria Luisa Moleti;Francesco Malaspina;Anna Maria Testi;Robin Foà;Fiorina Giona
2018

Abstract

Purpose: The aim of this study was to analyse the results of treatment with indomethacin as first line treatment in children and adults with Langerhans cell histiocytosis (LCH). Methods: Between 1999 and 2018, 47 patients with a diagnosis of LCH (CD1a+, S100+, CD207+) with a median age of 29 years (range 1-66) were treated with indomethacin 2 mg/Kg/day (maximum dose 150 mg/day) as first line (21 in combination with surgery and/or chemotherapy). Twentyseven patients (57.5%) had single system diseases (SS-LCH), 20 unifocal (74%) and 7 multifocal, and 20 (42.5%) presented multi-system involvement (MS-LCH). BRAF mutation analysis was available in 8/47 patients. Results: Thirty-eight of the 47 patients (81%) were evaluable for response. Two patients (4%) discontinued indomethacin due to toxicity. Considering patients evaluable for response, the median treatment duration was 3 months. All patients obtained a response, that was complete (CR) in 23 (60%) and intermediate (IR) in 15 (40%). Considering the disease status, 16/24 (66.6%) SS-LCH and 7/14 (50%)MS-LCH patients achieved a CR, while an IR was recorded in 8/24 (33.4%) SSLCH and in 7/14 (50%) MS-LCH patients. The CR rate was higher in patients treated with indomethacin as a single agent regimen (14/2, 66.6%) than in those who received a combination regimen (9/17, 53%). Disease reactivation occurred in 2/38 (5%) patients after 3 and 17 months, respectively, from treatment suspension. Three of 8 tested patients (37.5%) were BRAF mutated; all of them obtained a durable CR without recurrence. The most common toxicity was hypertension, recorded in 5/38 (13%) patients. All patients are alive. Conclusion: Our experience shows that indomethacin, used as single agent or in combination, is an effective first-line treatment, for SS-LCH and MS-LCH with bone involvement.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1284794
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact